You don't need to be signed in to read BMJ Blogs, but you can register here to receive updates about other BMJ products and services via our site.

James Raftery: Ever higher cancer drug prices—driven by US policies and genetic sequencing

1 Jul, 15 | by BMJ

The high prices charged by companies for cancer drugs has led to lots of speculation, but very little explanation. The most interesting attempt to explain these high prices has been made by a US oncologist Scott Ramsey. As the article is paywalled, I summarise it below (with thanks to the author for a copy).
His identifies two major factors: US health policies and technology. more…

James Raftery: The government response to the value based pricing consultation

26 Jul, 11 | by BMJ Group

The publication of the Government response to the value based pricing consultation provides some further insight into current thinking. 188 responses are summarised to the 20 questions posed in the consultation, along with the Department of Health response to each. Of the 20 questions, seven asked yes/no questions along the lines of do you agree that X is best. Given that such questions will have been crafted with mandarin nuance, one might be surprised if some gave the wrong answers. Several did. more…

James Raftery: What does “value based pricing” mean for NICE?

5 Jan, 11 | by BMJ

The “value based pricing” consultation paper” makes the following relevant references to the future of the National Institute for Health and Clinical Excellence (NICE). more…

James Raftery: Value based pricing – the consultation paper

30 Dec, 10 | by BMJ

The publication of the Department of Health’s consultation paper on value based pricing and the ongoing consultation on the Cancer Drugs Fund plus each consultation’s accompanying impact assessment mean that it is now possible to see what is being proposed. This blog looks at the essentials of value based pricing; later blogs will deal with more particular issues. more…

James Raftery on NICE’s cost per QALY threshold: does the public have a view?

12 Mar, 09 | by BMJ Group

One approach to setting NICE’s cost per QALY threshold might be to survey the public.  In 2003 NICE and the Department of Health did just that, with a study  “assessing  the feasibility of estimating the value that the UK population might attach to a QALY.” more…

James Raftery on a greater role for industry in NICE’s cost per QALY?

2 Mar, 09 | by BMJ Group

In December 2008 the Department of Health in England published the Pharmaceutical Price Regulation Scheme.  It describes how  the scheme will operate for at least five years from 2009. The previous scheme was to run to 2010 but the UK government withdrew it in February 2008 following a critical report from the Office of Fair Trading (OFT). more…

Vidhya Alakeson on US health reform

5 Jan, 09 | by BMJ Group

As with his presidential campaign, Barack Obama’s approach to health reform will leave little to chance. His strategy for enacting the first major coverage expansion in more than 40 years is starting to take shape. He is building public support for reform early in the hope that it will be enough to counter the opponents of healthcare reform when they eventually flex their muscles. more…

Joe Collier: A stab at future UK Drug Pricing Policy

3 Jul, 08 | by BMJ Group

Professor Joe CollierWe are now into the fifth month of the negotiations to reform the secretive and perverse (and essentially discredited) UK Pharmaceutical Price Regulation Scheme (PPRS), and we can safely assume that the discussions will be hotting up as the new terms must be in place by the beginning of September.


BMJ blogs homepage


Helping doctors make better decisions. Visit site

Creative Comms logo

Latest from The BMJ

Latest from The BMJ

Latest from BMJ podcasts

Latest from BMJ podcasts

Blogs linking here

Blogs linking here